Hedge funds have pushed their bullish exposure to U.S. healthcare stocks to nearly a five-year high, according to Goldman Sachs. Managers added exposure for a second straight week, buying across healthcare equipment, supplies, life-sciences tools, and pharmaceuticals. Goldman estimates healthcare deal volume could reach $173 billion in 2026, the highest since 2019, while AI-assisted drug discovery and an active transaction environment support positioning. Specialist healthcare hedge funds returned nearly 40% between August 2025 and April 2026, and 24% of new hedge funds launched in 2026 are dedicated to healthcare, the highest proportion since at least 2009.
Goldman Sachs Group IncGoldman Sachs is the source of the report highlighting bullish hedge fund positioning and deal volume forecasts, which may boost its investment banking and prime brokerage revenue.